Pulmonary Hypertension Successfully Treated With Stem Cells
Sleep apnea thickens blood vessels, increases heart disease risk
Obstructive sleep apnea, or periodic interruptions in breathing throughout the night, thickens sufferers' blood vessels.
The Importance of Early Diagnosis and Treatment of Pulmonary Arterial Hypertension
This study showed that early treatment can stabilize and potentially reverse the process of RV remodeling that can lead to RV dysfunction and death. Therefore, early recognition and prompt treatment may be the key to targeting the disease before initiation and progression of vascular remodeling and RV dysfunction occurs to achieve the best durable long-term outcome.
Gilead Sciences Initiates Enrollment in Phase II Clinical Trial Of Cicletanine Hydrochloride To Treat PAH - international news
Tuesday, Gilead Sciences Inc. (GILD: News) said it has initiated enrolling patients in a Phase II clinical trial of cicletanine hydrochloride, an oral agent in development for the treatment of pulmonary arterial hypertension.
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
OUTH SAN FRANCISCO, Calif.
Bayer Schering Pharma initiates Phase III program of lung drug
Bayer Schering Pharma has initiated a Phase III program with its oral agent riociguat. The two studies - Chest-1 and Patent-1 - will investigate the efficacy and safety of riociguat in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension. Over 700 patients will be recruited for the two studies.
Cold hands? Don't blame it on the weather: How icy fingers could be a sign of something more serious...
Cold hands are not only a sign that the weather's bitter - they could be a symptom of something more serious. There are at least a dozen conditions which cause chronic cold hands, including peripheral vascular disease and ME.
Bayer Starts Phase III Study Of Riociguat
Edited Press Release FRANKFURT -(Dow Jones)- German pharmaceutical maker Bayer AG (BAY.XE) said Monday its Bayer Schering Pharma unit has begun phase III program trials with the oral pulmonary agent riociguat.
Two phase III trials will investigate the application in patients with both chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
Female Hormones Deter Salt-Sensitive Hypertension
Salt-sensitive hypertension occurs when the kidneys hold onto more sodium than necessary.
Female Hormones Deter Salt-Sensitive Hypertension
Salt-sensitive hypertension occurs when the kidneys hold onto more sodium than necessary.